Mentice AB (publ.) a leading supplier of high-technology solutions for simulation in the medical sector with focus on endovascular procedures, presents its interim report for second quarter 2019.

Comments from CEO

First half year in line with our previous communications

Net sales for the first half year increased to SEK 59.8 million (56.3) which is equivalent to a growth of 6,2%.

We are confirming our short to medium term (next 3-5 years) financial target of a revenue growth of 30-40% per annum compounded, as stated in our first quarter interim report. For the current financial year, we are anticipating a revenue growth at the low end of this 30-40 % range.

As described further in this report we are managing a large span of opportunities where some of these might move into 2020. Our progress with Siemens Healthineers and Philips Healthcare is very positive and ahead of our expectation however actual ramp up for this business might be subject to a slight delay.

We have continued our investment for growth and during the first half of the year we increased the number of full-time equivalent staff members from 77 to 97 people. 

Full report is available as appendix or at www.mentice.com

For more information, please contact:

Göran Malmberg, CEO, Mentice

E-post: goran.malmberg@mentice.com

US Mobile. +1 (312) 860 5610

Sweden Mobile +46 (0) 703 09 22 22

This information is information that Mentice AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person, at 08.30 CET on August 29, 2019.  

Marketplace| Nasdaq First North Premier, Stockholm | Ticker symbol MNTC

Certified Adviser| FNCA Sweden AB, phone +46 8 528 00 399